Terray Therapeutics
750 Royal Oaks, Suite 100
Monrovia
CA
91016
United States
Website: http://www.terraytx.com/
Email: info@terraytx.com
About Terray Therapeutics
Terray is a biotechnology company with the technology, data, and mindset to radically change the way we discover and develop small molecule therapeutics. We explore molecules and targets broadly and deeply with a sophisticated integration of ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. Everything the company does is grounded in an iterative approach, producing massive amounts of precise, purpose-built data that gets increasingly valuable with each cycle of design and experimentation. The company’s platform uniquely blends experimentation and computation to improve the cost, speed, and success rate of small molecule drug discovery and development.
15 articles about Terray Therapeutics
-
Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb
12/14/2023
Terray Therapeutics today announced a multi-target collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to discover and develop small molecule therapeutics in certain disease areas.
-
Terray Therapeutics Announces Investment from NVIDIA to Enable Generative AI Design for Drug Discovery
11/9/2023
Terray Therapeutics announced an equity investment by NVentures, NVIDIA's venture capital arm.
-
Research associates are always in demand. Check out these top companies currently hiring RAs.
-
Terray Therapeutics Strengthens Leadership with Appointment of Sudha Parasuraman, MD to its Board of Directors
5/16/2023
Terray Therapeutics today announced the appointment of Sudha Parasuraman, MD, as an Independent Director.
-
Terray Therapeutics Appoints John Maraganore, Ph.D., as Strategic Advisor
12/13/2022
Terray Therapeutics today announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, has been appointed as Strategic Advisor to the Board of Directors and Leadership Team.
-
Terray Therapeutics Strengthens Leadership with Appointment of Bassil Dahiyat, Ph.D., as Board Independent Director
11/30/2022
Terray Therapeutics today announced the appointment of Bassil Dahiyat, Ph.D., as an Independent Director.
-
BioSpace's 2023 “Best Places to Work,” highlights innovative companies with a positive workplace culture, flexibility and strong leadership.
-
Terray Therapeutics and Calico Life Sciences struck a research and development collaboration focused on the development of small-molecule therapeutics for age-related diseases.
-
Terray Therapeutics Expands Scientific Advisory Board to Advance AI-Driven Small Molecule Drug Discovery
7/12/2022
Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the appointment of Fiona Black, PhD to its Scientific Advisory Board, adding valuable expertise in interdisciplinary technology development of both market-leading, end-to-end product solutions and operationally efficient and scalable manufacturing processes.
-
Kurma Partners earned €160 million in the first closing of its Growth Opportunities fund, and Atlas Venture raked in its largest round of funding yet to invest in new biotech firms.
-
Atlas Venture raised $450 million at the close of its thirteenth fundraising activity to support efforts to create and invest in new biotech firms that address many unmet patient needs.
-
BioSpace Movers & Shakers, March 4
3/4/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Terray Therapeutics Expands Leadership Team with Fez Ujjainwalla, PhD as Head of Business and Adam D. Hughes, PhD as Head of Chemistry
3/1/2022
Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, announced the appointments of Feroze Ujjainwalla, PhD, as Head of Business, and Adam D. Hughes, PhD, as Head of Chemistry.
-
Terray Therapeutics Launches with $60M to Deliver Premium Chemical Data at Unrivaled Scale, Unlocking the Potential of AI-Driven Small Molecule Drug Discovery
2/15/2022
Terray Therapeutics today announced the closing of a $60 million Series A financing to advance its novel tNova platform and deliver therapies to patients faster than ever before.
-
Terray Therapeutics has generated $60 million from a Series A financing round just shortly after getting $20 million in seed funding for the AI drug discovery.